Proprietary platform for neurological drug development
Targeting Parkinson's disease progression with CU-13001; Identifying druggable targets for neurological diseases; Detecting biomarker changes in patients; Developing early-stage neurology drug candidates; Supporting research with funding from major foundations
Supported by Stanford University and major foundations; Funded by the Michael J. Fox Foundation; Collaborations with Parkinson's UK and the National Institute on Aging